$ALDX - which reduces dryness and redness (only if used for allergy) has been shown to outdo $NVS Xiidra - a $400+ M/yr eye drop (2nd line) . $ALDX today is a $200M company - with promise. https://t.co/kPj4Eds9LM

“ $ALDX Reproxalap experience over 1 hr was superior to $NVS Xiidra. Improved performance of reproxalap innmost commonly reported side effects of Xiidra (ocular discomfort, blurry vision,dysgeusia) may result in greater patient adherence. https://t.co/qlr

Follicquick LLC excelente

$ALDX A Post-Acute Ocular Tolerability Comparison of Topical Reproxalap 0.25% and Lifitegrast 5% in Patients with Dry Eye Disease https://t.co/E1cGf7LcaD

RT @AldeyraALDX: Clinical Ophthalmology published the results of a study comparing the comfort of our lead RASP inhibitor, reproxalap, with…

RT @AldeyraALDX: Clinical Ophthalmology published the results of a study comparing the comfort of our lead RASP inhibitor, reproxalap, with…

Clinical Ophthalmology published the results of a study comparing the comfort of our lead RASP inhibitor, reproxalap, with lifitegrast in dry eye disease patients. Reproxalap consistently scored higher than lifitegrast on the measures of eye drop comfort: